Purposes: This is a non-comparative randomized phase II trial of preoperative taxane-anthracycline in combination with trastuzumab, lapatinib, or combined trastuzumab plus lapatinib in HER2 positive, stage II-IIIA operable breast cancer patients. Primary aim was to estimate the percentage of pathological complete response (pCR; no invasive tumor in breast and axillary nodes).Methods: in the three arms, chemotherapy consisted of weekly paclitaxel (80 mg/sqm) x 12 followed by FE75C x 4 courses q 3 weeks. The patients randomized to arm A received trastuzumab 4 mg loading dose followed by 2 mg weekly; in arm B patients received lapatinib 1500 mg p.o. daily; in arm C, patients received trastuzumab and lapatinib 1000 mg p.o. daily.Results: 121 patients have been randomized. Diarrhea, dermatologic, and hepatic toxicities were observed more frequently in patients receiving lapatinib. No episodes of congestive heart failure were observed. The rates of breast conserving surgery were 66.7%, 57.9% and 68.9% in arm A, B and C, respectively. The pCR rates were 25% (90%CI 13.1 to 36.9) in arm A, 26.3% (90%CI 14.5 to 38.1) in arm B, 46.7% (90%CI 34.4 to 58.9) in arm C (exploratory p= 0.0187).Conclusions: The primary end point of the study was met, with a relative increase of 80% in the pCR rate achieved with chemotherapy plus trastuzumab and lapatinib compared to chemotherapy plus either trastuzumab or lapatinib. These data add further evidence supporting the superiority of a dual-HER2 inhibition for the treatment of HER2 positive breast cancer.

Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study / Guarneri, Valentina; Frassoldati, A; Bottini, A; Cagossi, K; Bisagni, G; Sarti, S; Ravaioli, A; Cavanna, L; Giardina, G; Musolino, A; Untch, M; Orlando, L; Artioli, F; Boni, C; Generali, Dg; Serra, P; Bagnalasta, M; Marini, L; Piacentini, Federico; D'Amico, Roberto; Conte, Pierfranco. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 30:16(2012), pp. 1989-1995. [10.1200/JCO.2011.39.0823]

Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study

GUARNERI, Valentina;PIACENTINI, Federico;D'AMICO, Roberto;CONTE, Pierfranco
2012

Abstract

Purposes: This is a non-comparative randomized phase II trial of preoperative taxane-anthracycline in combination with trastuzumab, lapatinib, or combined trastuzumab plus lapatinib in HER2 positive, stage II-IIIA operable breast cancer patients. Primary aim was to estimate the percentage of pathological complete response (pCR; no invasive tumor in breast and axillary nodes).Methods: in the three arms, chemotherapy consisted of weekly paclitaxel (80 mg/sqm) x 12 followed by FE75C x 4 courses q 3 weeks. The patients randomized to arm A received trastuzumab 4 mg loading dose followed by 2 mg weekly; in arm B patients received lapatinib 1500 mg p.o. daily; in arm C, patients received trastuzumab and lapatinib 1000 mg p.o. daily.Results: 121 patients have been randomized. Diarrhea, dermatologic, and hepatic toxicities were observed more frequently in patients receiving lapatinib. No episodes of congestive heart failure were observed. The rates of breast conserving surgery were 66.7%, 57.9% and 68.9% in arm A, B and C, respectively. The pCR rates were 25% (90%CI 13.1 to 36.9) in arm A, 26.3% (90%CI 14.5 to 38.1) in arm B, 46.7% (90%CI 34.4 to 58.9) in arm C (exploratory p= 0.0187).Conclusions: The primary end point of the study was met, with a relative increase of 80% in the pCR rate achieved with chemotherapy plus trastuzumab and lapatinib compared to chemotherapy plus either trastuzumab or lapatinib. These data add further evidence supporting the superiority of a dual-HER2 inhibition for the treatment of HER2 positive breast cancer.
2012
30
16
1989
1995
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study / Guarneri, Valentina; Frassoldati, A; Bottini, A; Cagossi, K; Bisagni, G; Sarti, S; Ravaioli, A; Cavanna, L; Giardina, G; Musolino, A; Untch, M; Orlando, L; Artioli, F; Boni, C; Generali, Dg; Serra, P; Bagnalasta, M; Marini, L; Piacentini, Federico; D'Amico, Roberto; Conte, Pierfranco. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 30:16(2012), pp. 1989-1995. [10.1200/JCO.2011.39.0823]
Guarneri, Valentina; Frassoldati, A; Bottini, A; Cagossi, K; Bisagni, G; Sarti, S; Ravaioli, A; Cavanna, L; Giardina, G; Musolino, A; Untch, M; Orland...espandi
File in questo prodotto:
File Dimensione Formato  
CherLOB.pdf

Accesso riservato

Descrizione: Articolo principale
Tipologia: Versione pubblicata dall'editore
Dimensione 154.16 kB
Formato Adobe PDF
154.16 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/736695
Citazioni
  • ???jsp.display-item.citation.pmc??? 129
  • Scopus 319
  • ???jsp.display-item.citation.isi??? 284
social impact